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Abstract
Osteoblast differentiation and migration are necessary for bone formation during bone remodeling. 
Mice lacking the proline-rich tyrosine kinase Pyk2 (Pyk2-KO) have increased bone mass, in part 
due to increased osteoblast proliferation. Megakaryocytes (MKs), the platelet-producing cells, also 
promote osteoblast proliferation in vitro and bone-formation in vivo via a pathway that involves 
Pyk2. In the current study, we examined the mechanism of action of Pyk2, and the role of MKs, on 
osteoblast differentiation and migration. We found that Pyk2-KO osteoblasts express elevated 
alkaline phosphatase (ALP), type I collagen and osteocalcin mRNA levels as well as increased 
ALP activity and mineralization, confirming that Pyk2 negatively regulates osteoblast function. 
Since Pyk2 Y402 phosphorylation is important for its catalytic activity and for its protein-
scaffolding functions, we expressed the phosphorylation-mutant (Pyk2Y402F) and kinase-mutant 
(Pyk2K457A) in Pyk2-KO osteoblasts. Both Pyk2Y402F and Pyk2K457A reduced ALP activity, 
whereas only kinase-inactive Pyk2K457A inhibited Pyk2-KO osteoblast migration. Consistent with 
a role for Pyk2 on ALP activity, co-culture of MKs with osteoblasts led to a decrease in the level 
of phosphorylated Pyk2 (pY402) as well as a decrease in ALP activity. Although Pyk2-KO 
osteoblasts exhibited increased migration compared to WT osteoblasts, Pyk2 expression was not 
required for the ability of MKs to stimulate osteoblast migration. Together, these data suggest that 
osteoblast differentiation and migration are inversely regulated by MKs via distinct Pyk2-
dependent and independent signaling pathways. Novel drugs that distinguish between the kinase-
dependent or protein-scaffolding functions of Pyk2 may provide therapeutic specificity for the 
control of bone-related diseases.
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INTRODUCTION
Bone remodeling is controlled by the actions of the bone-degrading osteoclasts and bone-
forming osteoblasts [Delaisse, 2014; Florencio-Silva et al., 2015]. Bone formation at eroded 
bone surfaces begins with the recruitment of osteoblast precursors which undergo 
differentiation and maturation resulting in the secretion of a collagen matrix which is later 
mineralized by osteoblasts and osteocytes [Atkins et al., 2011; Ducy et al., 2000]. Although 
several key proteins involved in osteoblast function have been identified, much remains to be 
understood about the process of osteoblast recruitment, migration and differentiation into 
mature bone-forming cells.
The proline-rich tyrosine kinase Pyk2 is a member of the family of focal adhesion kinases. 
Our studies, and those of others, have reported the importance of the Pyk2 in bone 
remodeling in vivo [Avraham et al., 1995; Buckbinder et al., 2007; Cheng et al., 2013] and 
in bone cell function in vitro [Bruzzaniti et al., 2009; Duong et al., 2001; Eleniste and 
Bruzzaniti, 2012; Lakkakorpi et al., 2003; Wang et al., 2003]. Global deletion of the Pyk2 
gene in mice (Pyk2-KO mice) results in a high bone mass phenotype, which is in due to 
increased osteoblast activity [Buckbinder et al., 2007; Cheng et al., 2013] as well as 
decreased osteoclast activity [Gil-Henn et al., 2007]. Studies in osteoclasts reveal that Pyk2 
localizes to the actin-rich podosome ring (sealing zone) and promotes osteoclast maturation 
and bone resorption [Bruzzaniti et al., 2009; Duong et al., 2001; Gil-Henn et al., 2007; 
Miyazaki et al., 2004; Zhang et al., 2002]. Upon integrin engagement and in response to 
increased intracellular Ca2+ levels, Pyk2 is auto-phosphorylated at tyrosine residue Y402 
[Duong et al., 1998; Park et al., 2004; Sanjay et al., 2001]. Tyrosine 402 phosphorylation is 
necessary for the maximal catalytic activity of Pyk2 [Duong et al., 1998; Park et al., 2004; 
Sanjay et al., 2001]. In addition, phosphorylation of Pyk2 at Y402 forms a consensus 
binding site for SH2-containing proteins [Dikic et al., 1996] and is involved in the activation 
of downstream signaling cascades [Avraham et al., 2000; Dikic et al., 1996; Faccio et al., 
2003]. Indeed, Pyk2 autophosphorylation, but not its kinase activity, has been shown to be 
important for the adhesion-induced association of Pyk2 with c-Src in osteoclasts 
[Lakkakorpi et al., 2003; Miyazaki et al., 2004]. Thus, Pyk2 cellular function goes beyond 
its kinase activity.
In osteoblasts, the actions of Pyk2 are not well characterized. We reported that the 
proliferation of osteoblasts is increased in cultures containing megakaryocytes (MKs), the 
blood cells responsible for the production of thrombocytes [Ciovacco et al., 2010; Kacena et 
al., 2012; Kacena et al., 2004]. The increase in osteoblast proliferation by MKs in vitro is 
mediated, in part, by increased expression of the Pyk2 gene as well as the activation of 
integrin receptors. Consistent with these findings, MKs did not increase the bone mass of 
Pyk2−/− mice, suggesting the important role of Pyk2 in the MK-induced increase in 
osteoblast proliferation and bone volume [Cheng et al., 2013]. In the current study, we 
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examined further the mechanism of action of Pyk2 in osteoblast differentiation and 
migration. We focused on the role of Pyk2 kinase activity and Y402 phosphorylation on 
osteoblast differentiation and migration. In addition, we examined the effect of MKs on 
Pyk2 Y402 phosphorylation in osteoblasts, and the role of MKs on osteoblast migration in 
the presence or absence of Pyk2.
MATERIALS AND METHODS
MATERIALS
Antibodies used for Western blot analyses were obtained from Transduction Laboratories 
(Lexington, KY). An antibody to phosphorylated Pyk2-Y402 was obtained from Biosource 
International. Anti-hemagglutinin (anti-HA) to detect transfected Pyk2 was from Bethyl 
Laboratories (Montgomery, TX). Horseradish peroxidase-conjugated anti-rabbit and anti-
mouse secondary antibodies were obtained from Fisher Scientific (Fairlawn, NJ). 
Phenylarsine oxide (PAO) was purchased from Sigma-Aldrich (St. Louis, MO).
PREPARATION OF NEONATAL CALVARIAL CELLS
All animals were maintained, bred and handled following the guidelines of the American 
Association for Laboratory Animal Science using Institutional Animal Care and Use 
Committee (IACUC) approved protocols and in according with the NIH (Guide for the Care 
and Use of Laboratory Animals, 1996). Murine calvarial cells from C57BL/6 (WT) and 
Pyk2−/− (Pyk2-KO) mice were prepared using a modification of a previous protocol [Jilka 
and Cohn, 1981; Simmons et al., 1982; Wong and Cohn, 1975]. Briefly, calvaria from 
neonatal mice were incubated with EDTA in PBS for 30 min. The calvaria were subjected to 
sequential collagenase digestions and fractions 3–5 were collected. These cells were 
assessed by a variety of criteria to be over 95% enriched for osteoblasts or osteoblast 
precursors [Boutahar et al., 2004; Guignandon et al., 2006; Richardson and Parsons, 1996]. 
Osteoblast cultures were expanded and further enriched by passaging 3 times and aliquots 
were frozen in liquid nitrogen until required. For experimentation, osteoblasts were thawed 
and allowed to recover for 3 days before being seeded at 2x104 cells per well in 6-well 
plates.
PREPARATION OF MEGAKARYOCYTES
MKs were prepared as previously described [Kacena et al., 2006; Kacena et al., 2004]. 
Briefly, embryonic E13–15 fetuses were dissected from pregnant WT mice, fetal livers were 
removed and single cell suspensions were generated. Cells were washed and then seeded in 
100 ml culture dishes in Dulbecco modified eagle medium (DMEM) supplemented with 
10% FCS and 1% murine thrombopoietin [Villeval et al., 1997]. MKs were isolated 5–7 
days later by separating them from the lymphocytes and other cells using a one-step albumin 
gradient to obtain a 90–95% pure MK population [Drachman et al., 1997].
GENERATION OF RECOMBINANT ADENOVIRUSES
Recombinant adenoviruses expressing active WT Pyk2 (Pyk2WT), kinase-inactive 
Pyk2K457A and Pyk2Y402F were previously described [Gil-Henn et al., 2007; Sanjay et al., 
2001]. Briefly, pShuttle plasmids (Qbiogene) containing Pyk2 were used for infection of 
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primary osteoblasts. Recombinant adenoviruses expressing WT Pyk2 or its mutants were 
prepared by recombination of the above plasmids using the Adenovator Vector System 
(Qbiogene) according to the manufacturer’s instructions. Adenoviruses with similar MOIs 
(multiplicity of infection) were used. Infection was performed for 3 days which showed 
maximal protein expression. Western blot analysis was used to confirm expression levels of 
the Pyk2 proteins in osteoblasts after 3 days of infection.
IMMUNOPRECIPITATION ASSAYS
Immunoprecipitation (IP) assays were performed as previously described [Bruzzaniti et al., 
2009; Eleniste et al., 2012]. Cells were lysed in buffer containing 50 mM Tris-Cl, 150 mM 
NaCl, 1% NP-40, 0.25% sodium deoxycholate, and protease and phosphatase inhibitors (1 
mM phenylmethylsulfonyl fluoride, 1 mM NaF, 1 mM sodium orthovanadate, and 10 μg/ml 
each of leupeptin, aprotinin, and pepstatin). Lysates were sonicated and the supernatant 
clarified by centrifugation. IPs were performed with protein G-agarose beads for 1 h. After 
binding and washing, the samples were heated to 100°C in sample buffer and resolved by 
SDS-PAGE. Western blot analysis was performed using the enhanced chemiluminescence 
detection kit (Amersham) with multiple exposure times. The phospho-Y402 antibody was 
specific for Pyk2 as determined by Western blot analysis of immunoprecipitated Pyk2 and 
did not detect immunoprecipitated mutant Pyk2Y402F. All experiments were performed a 
minimum of three times, and representative blots or images are shown as indicated. The 
intensity of protein bands in Western blots were analyzed and normalized by densitometric 
analysis using NIH-ImageJ software.
QUANTITATIVE REAL-TIME PCR
Total RNA was isolated using RNAeasy kit (Qiagen). DNAse (Qiagen)-treated RNA was 
used to generate cDNA by reverse transcription according to the manufacturer’s instructions 
(SuperScript II kit; Invitrogen). PCR reactions were performed in an MX3000 detection 
system using SYBR green PCR reagents following the manufacturer’s instructions. For each 
gene, a calibration curve was performed. All oligonucleotide primers were tested to ensure 
correct specificity and sensitivity. For each sample, arbitrary units obtained using the 
standard curve and the expression of GAPDH was used to normalize the amount of the 
investigated transcript. The following primer sequences were used:
Alkaline phosphatase forward primer: 5′ GCTGATCATTCCCACGTTTT
Alkaline phosphatase reverse primer: 5′ CTGGGCCTGGTAGTTGTTGT
Osteocalcin forward primer: 5′ AAGCAGGAGGGCAATAAGGT
Osteocalcin reverse primer: 5′ TTTGTAGGCGGTCTTCAAGC
Type I collagen forward primer: 5′ CAGGGAAGCCTCTTTCTCCT
Type I collagen reverse primer: 5′ ACGTCCTGGTGAAGTTGGTC
GAPDH forward primer: 5′ CGTGGGGCTGCCCAGAACAT
GAPDH reverse primer: 5′ TCTCCAGGCGGCACGTCAGA
ALKALINE PHOSPHATASE ACTIVITY AND STAINING
Osteoblasts were cultured for up to 21 days in osteogenic media containing 10 μM ascorbic 
acid and 50 μM β-glycerolphosphate. For alkaline phosphatase (ALP) staining, cells were 
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fixed in 10% formalin and stained as previously detailed [Ciovacco et al., 2009]. 
Alternatively, osteoblasts were cultured for 14 days in osteogenic media and calcium 
deposition was quantified using Alizarin Red-S as a functional measure of osteoblast 
mineralization as previously described [Stanford et al., 1995].
MIGRATION ASSAYS
Osteoblast migration assays were performed using Culture-Insert μ-Dishes as described by 
the manufacturer (Ibidi). Primary WT or Pyk2-KO osteoblasts were seeded into the inner 
well of the μ-Dish and incubated at 37°C and 5% CO2 overnight. Alternatively, prior to 
plating in migration chambers, primary osteoblasts were infected with adenovirus expression 
constructs for Pyk2 using multiplicity of infection (MOI) of 300 per virus for 3 days. The 
migration chamber inserts were removed, unattached cells were rinsed off, and osteoblasts 
were incubated with alpha-MEM containing 10% serum for 6 hours. The migration of cells 
into the clear zone outside of the plating area was quantified microscopically. For migration 
assays involving MKs, 1x105 osteoblasts were first plated into migration chambers and 
incubated overnight. The following day, chamber inserts were removed and osteoblasts were 
imaged before adding 1x104 MKs to each well. Osteoblasts plus MK co-cultures were then 
incubated for an additional 6 hr, after which the cells were fixed in 4% formaldehyde. 
Osteoblast migration distance was determined by microscopic imaging using a Leica 
DMI4000B inverted microscope with attached digital camera. Final analyses were 
performed using Image Pro software (Media Cybernetics, Bethesda, MD).
STATISTICAL ANALYSES
All data was reproduced a minimum of three time. The average plus/minus standard error of 
the mean is shown as indicated. The statistical significance level was set at 0.05% (p<0.05) 
and data was analyzed using two-tailed distribution and equal variance student t-Test.
RESULTS
OSTEOBLAST DIFFERENTIATION IS INCREASED IN THE ABSENCE OF PYK2
Osteoblast differentiation is characterized by an early increase in alkaline phosphatase 
(ALP) followed by an increase in collagen type 1 and later osteocalcin. To examine the role 
of Pyk2 on osteoblast differentiation, calvarial osteoblasts were isolated from WT and Pyk2-
KO mice and cultured under osteogenic conditions containing ascorbic acid and β-
glycerolphosphate for 7 days. Osteoblasts were then stained for ALP. In addition, osteoblasts 
were cultured for 21 days and then stained with Alizarin-S red, which stains bound calcium 
and is used as a measure of the ability of osteoblasts to mineralize the collagen matrix (Fig. 
1A). Consistent with published studies [Buckbinder et al., 2007], Pyk2-KO osteoblasts 
exhibited higher levels of ALP staining and were more active in calcium deposition than 
wild-type (WT) osteoblasts. Similar effects were observed when bone marrow-derived 
stromal osteoblasts from WT and Pyk2-KO mice were compared (data not shown). The 
expression of the osteoblastic genes, ALP, collagen type I and osteocalcin were also 
analyzed by quantitative PCR (QPCR) and were found to be significantly higher in Pyk2-
KO osteoblasts than WT osteoblasts (Fig. 1B) confirming that Pyk2 is a negative regulator 
of osteoblast differentiation.
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ALP ACTIVITY IS INHIBITED BY PYK2 PHOSPHORYLATION AND KINASE MUTANTS
The phosphorylation of Pyk2 at Y402 not only elevates Pyk2’s catalytic activity but also 
promotes its association with its binding partners such as c-Src [Avraham et al., 2000; Dikic 
et al., 1996; Faccio et al., 2003][Lakkakorpi et al., 2003]. Therefore, to begin to examine the 
mechanism of action of Pyk2 in osteoblasts, we determined the extent to which Pyk2 was 
phosphorylated at Y402 (pY402), in osteoblasts under steady-state conditions. However, 
Pyk2 pY402 levels in WT osteoblasts were generally difficult to detect by Western blotting 
using a phospho-specific antibody (Fig. 2A, lane 1). Therefore, osteoblasts were treated with 
phenylarsine oxide (PAO), a broad spectrum chemical inhibitor of tyrosine phosphatases. As 
anticipated, Pyk2 Y402 phosphorylation was increased in a dose-dependent manner 
suggesting that Pyk2 phosphorylation was negatively regulated by protein-tyrosine 
phosphatases in osteoblasts.
The tight regulation of Y402 phosphorylation in osteoblasts indicated that Pyk2 
phosphorylation may have effects on osteoblast function that are distinct from its kinase 
activity. We therefore compared the effects of Pyk2 phosphorylation or kinase activity on 
osteoblast differentiation. To test this, Pyk2-KO osteoblasts were infected with adenoviruses 
expressing normal (Pyk2WT), an auto-phosphorylation mutant (Pyk2Y402F) or a kinase-
inactive mutant (Pyk2K457A). Note that in the Y402F mutant, tyrosine residue 402 is 
replaced by phenylalanine which removes the c-Src binding site and previous studies have 
revealed that targeting Src kinase is critical for the cellular function of Pyk2 [Lakkakorpi et 
al., 2003; Miyazaki et al., 2004]. In this experiment, the infected osteoblast cells were 
differentiated for 3 days instead of 7 days which maximized viral titer and viral protein 
expression. After 3 days in osteogenic media, the cells were stained for ALP (Fig. 2B) or 
assayed using a quantitative biochemical ALP activity assay in vitro (Fig. 2C). Uninfected 
Pyk2-KO osteoblasts and WT osteoblasts were used as controls. Consistent with an increase 
in ALP protein staining levels observed in Pyk2-KO after 7 days (Fig. 1), Pyk2-KO 
exhibited elevated ALP activity compared to WT osteoblasts after 3 days in culture (Fig. 
2B). However, re-expression of Pyk2WT in Pyk2-KO osteoblasts had little effect on ALP 
staining or ALP activity. In contrast, in Pyk2-KO osteoblasts expressing either Pyk2Y402F or 
Pyk2K457A, ALP activity was significantly lower than in control osteoblasts. These findings 
suggested that inhibiting either the Y402 phosphorylation or the kinase activity of Pyk2 
suppressed ALP activity and decreased osteoblast differentiation. Similar to our findings 
using primary osteoblasts, MC3T3-E1 osteoblastic cells transiently expressing Pyk2Y402F or 
Pyk2K457A cDNA showed decreased ALP activity compared to cells expressing Pyk2WT 
cDNA (data not shown). These finding confirmed the reproducibility of our findings in an 
osteoblastic cell model and suggested our current findings were not due to the use of 
adenoviruses.
OSTEOBLAST MIGRATION IS REGULATED BY PYK2 Y402 PHOSPHORYLATION
Osteoblast migration is critical for their recruitment to eroded bone surfaces. Therefore, we 
examined the role of Pyk2 phosphorylation and kinase activity on cell migration. Pyk2-KO 
osteoblasts were infected with adenoviruses expressing similar amounts of Pyk2WT, 
Pyk2Y402F, or Pyk2K457A. After 3 days, osteoblasts were replated into migration chambers. 
Microscopic imaging was performed at 0 and 6 hours and the distance traveled was 
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quantified (Fig. 3A). Compared to WT osteoblasts, control Pyk2-KO osteoblasts (no virus) 
displayed an increase in migration distance of approximately 40–60%. Consistent with an 
inhibitory role for Pyk2 during osteoblast migration, adenovirus-expressed Pyk2WT 
decreased Pyk2-KO migration by 40% and was similar to WT osteoblast (no virus) levels 
(Fig. 3B). Pyk2K457A also significantly decreased the migration of Pyk2-KO osteoblasts. 
However, Western blotting confirmed significantly lower expression levels of Pyk2K457A 
than Pyk2WT. In contrast, Pyk2Y402F had little effect on Pyk2-KO osteoblast migration even 
when its expression level was allowed to exceed that of Pyk2WT in Pyk2-KO osteoblasts or 
endogenous Pyk2 in WT osteoblasts (Fig. 3C). Taken together, these data reveal that kinase-
inactive Pyk2K457A, but not the phosphorylation mutant Pyk2Y402F, represses Pyk2-KO 
osteoblast migration. These findings also suggested that kinase-inactive Pyk2K457A was 
more effective at reducing Pyk2-KO osteoblast migration than Pyk2WT which retains 
catalytic activity and the ability to be phosphorylated.
MEGAKARYOCYTES REDUCE PYK2 PHOSPHORYLATION AND ALP ACTIVITY
We previously reported that Pyk2 plays a role in the mechanism by which megakaryocytes 
(MK) increase osteoblast number in vitro and bone mass in vivo [Cheng et al., 2013]. A role 
for Pyk2 in the actions of MKs is also supported by the finding that Pyk2 tyrosine 
phosphorylation in platelets is stimulated by phorbol 12-myristate 13-acetate (PMA), a 
known protein kinase C (PKC) agonist [Ohmori et al., 2000]. Therefore, we examined if 
MKs regulated Pyk2 phosphorylation in osteoblasts. We also determined the extent to which 
MKs regulated Pyk2 phosphorylation in the presence or absence of PMA (Fig. 4). For these 
studies, osteoblasts were co-cultured with MKs for up to 24 hours and then MKs were 
removed by extensive washing. Osteoblast cultures (devoid of MKs) were treated with PMA 
or vehicle for 1 hour prior to harvesting and Western blotting. Phosphorylated Pyk2 was 
identified by Western blotting using an antibody to phosphorylated Y402. Densitometry was 
used to determine changes in the ratio of phosphorylated Pyk2 (pY402) to total Pyk2 
(pY402/Pyk2).
Similar to previous studies [Cheng et al., 2013], total Pyk2 levels were increased when 
osteoblasts were cultured in the presence of MKs for 24 hours. However, in osteoblasts co-
cultured with MKs, the ratio of pY402 to total Pyk2 (pY402/Pyk2) was consistently lower 
than in control osteoblasts without MKs for all incubation periods (1–24 hr). These findings 
suggested that MKs inhibit Pyk2 phosphorylation in osteoblasts. In osteoblasts treated with 
PMA, we observed a time-dependent increase in Pyk2 phosphorylation levels compared to 
control osteoblasts, especially at 24 hr when a 5-fold increase in the pY402/Pyk2 ratio was 
observed. However, PMA failed to significantly increase the pY402/Pyk2 ratio in osteoblasts 
pre-cultured with MKs. Taken together, these findings suggest that Pyk2 phosphorylation is 
activated by PMA, most likely via activation of PKC, and that MKs prevent the PMA-
stimulated increase in Pyk2 phosphorylation in osteoblasts.
Given that MKs decreased Pyk2 phosphorylation (lowered the pY402/Pyk2 ratio) in the 
presence or absence of PMA and that Pyk2Y402F expression in Pyk2-KO osteoblasts had an 
inhibitory effect on ALP activity (Fig. 2), we examined the effect of MKs on ALP activity in 
osteoblasts. MKs were cultured with osteoblasts for ten days and then removed by washing 
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prior to assaying ALP activity. As shown in Fig. 4B, OBs co-cultured with MKs showed a 
robust 3.5-fold reduction in ALP activity compared to OBs cultured alone, which 
reproduced our previously published studies [Ciovacco et al., 2009]. Thus, our findings 
suggest that the MKs act in part to decrease Pyk2 phosphorylation which decreases ALP 
activity and osteoblast differentiation.
MEGAKARYOCYTES PROMOTE OSTEOBLAST MIGRATION INDEPENDENT OF PYK2
Given that Pyk2 phosphorylation was found to be important for regulating ALP activity but 
was not required for osteoblast migration, we examined the extent to which MKs regulate 
osteoblast migration and whether Pyk2 was required for this process. Osteoblasts from WT 
or Pyk2-KO mice were plated in migration chambers overnight. The next morning 
osteoblasts were co-cultured in the absence or presence of MKs for 6 hours. As shown in 
Fig. 5, MKs stimulated the migration of WT osteoblasts by 24±5 percent, compared to 
osteoblasts cultured alone. The basal migration of Pyk2-KO is higher than that of WT 
osteoblasts as shown in Fig 3. In the presence of MKs, the migration of Pyk2-KO osteoblasts 
is increased by 31±12 percent. However, no significant difference was observed between the 
effects of MKs on the migration of WT or Pyk2-KO osteoblasts, suggesting that the 
stimulatory effect of MKs on osteoblast migration is independent of Pyk2 expression.
DISCUSSION
Bone formation by osteoblasts is crucial for bone modeling and remodeling as well as 
fracture repair. We and others have demonstrated that Pyk2-KO mice exhibit higher bone 
mass than WT mice which is due to increased osteoblast activity and decreased osteoclast 
bone resorbing activity [Buckbinder et al., 2007; Gil-Henn et al., 2007]. We also reported 
that Pyk2 regulates the stimulatory effects of MKs on bone formation and osteoblast number 
[Cheng et al., 2013]. Pyk2 phosphorylation at Y402 is necessary for the activation of 
downstream signaling cascades [Avraham et al., 2000; Dikic et al., 1996; Faccio et al., 
2003], as well as for maximal catalytic activity against its substrates [Duong et al., 1998; 
Park et al., 2004; Sanjay et al., 2001]. In support of this, we demonstrated that bone 
resorption was inhibited in osteoclasts over-expressing Pyk2Y402F or kinase-inactive 
Pyk2K457A [Gil-Henn et al., 2007; Lakkakorpi et al., 2003]. Of interest, Lakkakorpi et al. 
(2003) also showed that Pyk2 autophosphorylation, but not Pyk2 kinase activity was 
necessary for the association of Pyk2 with c-Src in osteoclasts [Lakkakorpi et al., 2003; 
Miyazaki et al., 2004]. Thus, cellular function of Pyk2 extends beyond simply its kinase 
activity and is likely to involve its non-enzymatic protein subdomains, including two 
protein-rich domains which bind SH3-containing proteins.
In the current study, we examined the mechanism of action of Pyk2 in osteoblasts. We 
focused on elucidating the role of Pyk2 phosphorylation and kinase activity in the function 
of osteoblasts. We demonstrated that osteoblasts lacking Pyk2 show a significant increase in 
ALP mRNA levels, ALP catalytic activity, and mineralizing activity (Ca2+ deposits). In 
addition, type I collagen and osteocalcin mRNA expression, which are markers of mature 
osteoblast activity, were increased, supporting the role for Pyk2 as a negative regulator of 
osteoblast differentiation. Furthermore, our studies reveal that Pyk2 phosphorylation and 
Eleniste et al. Page 8
J Cell Biochem. Author manuscript; available in PMC 2017 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
activity have distinct effects on the differentiation and migration of osteoblasts. Finally, we 
demonstrated that although Pyk2 is important for osteoblast migration, MKs can also 
promote osteoblast migration by a process that is independent of Pyk2 gene expression.
Based on our finding that basal Pyk2 phosphorylation is low in WT osteoblasts, and the fact 
that over-expression of Pyk2Y402F decreases ALP activity in Pyk2-KO osteoblasts, we 
speculate that the ratio of pY402/total Pyk2 regulates ALP activity. Consistent with this, 
cellular events that inhibit Pyk2 phosphorylation, such as co-culture of osteoblasts with 
MKs, decrease Pyk2 phosphorylation and correspondingly decrease ALP activity. We also 
found that the kinase-inactive mutant of Pyk2 (Pyk2K457A) had a negative effect on ALP 
mRNA in Pyk2-KO osteoblasts whereas Pyk2WT had little effect on ALP activity. These 
findings are consistent with published findings showing that kinase-inactive Pyk2 fails to 
enhance ALP activity in human mesenchymal stem cells [Buckbinder et al., 2007]. It is 
important to point out that ALP is itself a phosphatase and we previously showed that the 
protein phosphatase PTP-PEST negatively regulates Pyk2 activity [Eleniste et al., 2012]. 
Whether ALP can inhibit Pyk2 (directly or indirectly via other proteins) or whether 
Pyk2K457A can act as dominant-negative inhibitor of the catalytic activity of ALP is 
unknown. It is also possible that Pyk2-KO osteoblasts expressed maximal ALP enzymatic 
activity preventing a further increase in ALP activity. In contrast to our results which showed 
that Pyk2Y402F inhibited ALP activity, others have reported that a chemical inhibitor of 
Pyk2, which can block Pyk2-Y402 phosphorylation, increases ALP levels in MC3T3 cells, 
an immortalized pre-osteoblastic cell line [Allen et al., 2009]. This discrepancy may be due 
to use of an immortalized cell by Allen et al. (2009) or that MC3T3 cells were cultured for 
two-three weeks prior to examining ALP activity. Furthermore, the authors did not report if 
long-term culture of MC3T3 cells with the Pyk2 inhibitors affected Pyk2 mRNA or protein 
levels.
Pyk2 is activated following engagement of integrins, resulting in its autophosphorylation at 
Y402 [Duong et al., 1998; Park et al., 2004; Pfaff and Jurdic, 2001; Sanjay et al., 2001]. 
Although [Ca2+]i is required for Pyk2 activity, the induction of Pyk2’s full catalytic activity 
also requires the binding of the Src SH2 domain to phosphorylated Pyk2-Y402 and the 
subsequent phosphorylation of additional C-terminal tyrosine residues [Duong et al., 1998; 
Park et al., 2004; Sanjay et al., 2001]. We found that in the absence of Pyk2, osteoblast 
migration is significantly enhanced. Although Pyk2Y402F (auto-phosphorylation mutant) 
inhibited ALP activity, it did not affect the migration of Pyk2-KO osteoblasts. In contrast, 
kinase-dead Pyk2K457A inhibited both ALP activity and the migration of Pyk2-KO 
osteoblasts. These findings suggest that eliminating the Src binding site on Pyk2 (Y402F) 
likely affects its ability to recruit Src or other downstream scaffolding proteins such as 
vinculin and paxillin which are also required for cellular adhesion and migration [Duong and 
Rodan, 2000; Eleniste and Bruzzaniti, 2012; Kintscher et al., 2001]. Of interest, recent 
evidence suggests that the activation of Pyk2 in response to fibroblast growth factor receptor 
3 (FGFR3) signaling is independent of Y402 phosphorylation, obviating the requirement for 
Src recruitment to Y402 in some instances [Meyer et al., 2004].
We previously reported that Pyk2 dephosphorylation in osteoclasts occurs through the 
actions of the protein tyrosine phosphatase PTP-PEST [Eleniste et al., 2012]. Unlike 
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osteoclasts in which phosphorylated Pyk2 is readily detectable, we detected only low levels 
of phosphorylated Pyk2 in wild-type osteoblasts. However, similar to osteoclasts, Pyk2 
phosphorylation in osteoblasts was induced by treatment with phenylarsine oxide (PAO) 
(Fig. 2) and orthovanadate (data not shown), two broad specificity phosphatase inhibitors. In 
addition, we found that Pyk2-Y402 phosphorylation was stimulated by PMA (Fig. 4), a 
known protein kinase C agonist [Ohmori et al., 2000]. Moreover, we found that co-culture of 
osteoblasts with MKs leads to an increase in Pyk2 levels and a corresponding decrease in the 
ratio of pY402/Pyk2. Taken together, these findings suggest that the Pyk2 phosphorylation/
dephosphorylation cycle is tightly regulated by upstream and downstream signaling cascades 
and that sustained Pyk2 phosphorylation is detrimental to osteoblast function.
We recently reported that osteoblasts express two isoforms of Pyk2; full-length Pyk2 and a 
shorter splice variant known as Pyk2-S which lacks a 42 amino acid mid-molecule domain 
[Kacena et al., 2012]. Our studies also reveal that co-culture of MK with osteoblasts 
promotes Pyk2-S mRNA expression but decreases Pyk2 mRNA in osteoblasts [Kacena et 
al., 2012]. In the current study, we found that MK-stimulation of osteoblasts increases total 
Pyk2 levels, mostly likely Pyk2-S, which is largely non-phosphorylated as shown by the low 
pY402/Pyk2 ratio. Although PMA increased the pY402/Pyk2 ratio in untreated osteoblasts, 
pY402 levels were low after PMA stimulation of osteoblasts co-cultured with MKs. This 
was particularly evident in the 16 and 24 hours co-cultures. Given that the MKs increase the 
expression of the shorter Pyk2-S isoform (our previous publication), these findings may 
suggest that Pyk2-S is not responsive to a PMA/PKC-mediated increase in phosphorylation. 
Additional studies will be required to determine if MKs act to prevent Pyk2 phosphorylation 
or enhance Pyk2 dephosphorylation. In addition, it remains to be determined whether Pyk2 
or Pyk2-S exhibit distinct functional roles in osteoblasts in response to MK stimulation.
MKs promote osteoblast proliferation (our previous studies) and cell growth but inhibit ALP 
activity in vitro (Fig. 4). We demonstrated that mice deficient in the MK transcription factor, 
GATA-1, exhibit a profound increase in bone marrow MKs and exhibit a marked increase in 
osteoblast number and bone mass [Drachman et al., 1997; Kacena et al., 2005; Kacena et al., 
2006; Kacena et al., 2004; Villeval et al., 1997]. Our current studies provide a potential 
Pyk2-regulated mechanism for the MK-mediated decrease in ALP. That is, our findings 
suggest that MKs inhibit Pyk2 phosphorylation which decreases ALP activity and inhibits 
osteoblast differentiation, favoring osteoblast proliferation.
The process of bone formation is preceded by the recruitment of osteoblasts to eroded bone 
surfaces. However, the role of Pyk2 phosphorylation and/or kinase activity and the role of 
MKs in osteoblast migration had not previously been examined. To this end, we examined if 
MKs regulated osteoblast migration and the role of Pyk2 in this process. Our findings 
demonstrate that Pyk2Y402F had little effect on Pyk2-KO osteoblasts migration, although 
basal Pyk2-KO osteoblast migration was higher than WT osteoblasts. In contrast to 
Pyk2Y402F, kinase-dead Pyk2K457A repressed osteoblast migration, which is consistent with 
published reports that pharmacologic Pyk2 inhibitors inhibit cancer cell migration and 
metastasis [Han et al., 2009; Tse et al., 2012; Walker et al., 2009]. We also report for the first 
time that MKs promote osteoblast migration in a process that is independent of Pyk2 
expression. Together, these findings suggest that the ability of MKs to promote bone 
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formation and osteoblast proliferation (our previous studies), while conversely inhibiting 
osteoblast differentiation in vitro (this study and Ciovacco et al., 2009) may in part be 
explained by the sum effect of Pyk2-dependent and independent actions of MKs. That is, 
MKs decrease osteoblast differentiation by decreasing Pyk2-phosphorylation (favoring 
osteoblast proliferation) and MKs promote osteoblast migration to eroded bone surfaces via 
a process that is independent of Pyk2. Since MKs are short lived, the net increase in 
osteoblast number may ultimately lead to an increase in bone volume.
In summary, our findings indicate the presence of unique and overlapping Pyk2 signaling 
pathways in osteoblasts, which may be controlled by regulating the phosphorylation, kinase 
activity and scaffolding functions of Pyk2. Our data demonstrate that osteoblast migration 
and bone-forming activity are functionally enhanced in the absence of Pyk2, and that 
inhibition of Pyk2 Y402 phosphorylation plays a significant role in osteoblast differentiation 
(decreased ALP activity) but not migration. Furthermore, MKs promote osteoblast 
differentiation and migration via distinct Pyk2-dependent and independent pathways, 
respectively. Therefore, new therapeutic approaches that selectively target Pyk2 
phosphorylation or MK-induced pathways in osteoblasts may provide specificity for the 
treatment of different bone-related diseases such as osteoporosis, bone regeneration or tumor 
metastasis.
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Fig. 1. Osteoblast differentiation is impaired in the absence of Pyk2
Two day calvarial osteoblasts (OB) were generated from WT and Pyk2-KO mice. (A) 
Osteoblasts were cultured under osteogenic conditions containing ascorbic acid and β-
glycerolphosphate for 7 days and then stained for alkaline phosphatase expression or 
cultured for 21 days and stained with Alizarin-S red as a measure of osteoblast 
mineralization. (B) QPCR analysis was used to determine mRNA expression of osteoblastic 
genes; ALP, type I collagen, and osteocalcin. GAPDH was used as the control to normalize 
the amount of the mRNA transcript under investigation. The mean of duplicate samples is 
shown for each transcript ± standard error of the mean (SEM). Experiments were performed 
a minimum of 3 times and representative data are shown. The asterisks (*) indicate statistical 
significance (p<0.05) relative to control WT osteoblasts set at RQ 1.0.
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Fig. 2. Pyk2-KO osteoblast differentiation is inhibited by Pyk2Y402F and Pyk2K457A, but not 
Pyk2WT
(A) WT osteoblasts were treated with 5 or 10 μm PAO for 1 hr. Lysates were 
immunoprecipitated with anti-Pyk2 and blotted for phosphorylated tyrosine (p-Tyr) or using 
a phosho-specific p-Y402 antibody. Membranes were reblotted for total Pyk2 as a control. 
The Pyk2 antibody detects Pyk2WT, Pyk2Y402F and Pyk2K457A. (B–C) Pyk2-KO 
osteoblasts were infected with adenoviruses expressing similar amounts of Pyk2WT (active), 
Pyk2Y402F (phosphorylation mutant), or Pyk2K457A (kinase-inactive). Osteoblasts were 
cultured for 3 days in osteogenic media and (B) stained for ALP or (C) assayed for ALP 
activity. Experiments were reproduced 4 times using different amounts of viruses, with 
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consistent results. Representative data are shown. The asterisk (*) indicates statistical 
significance relative to controls.
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Fig. 3. Pyk2Y402F does not inhibit migration in Pyk2-KO osteoblasts
Pyk2-KO osteoblasts were infected with adenoviruses expressing Pyk2WT, Pyk2Y402F or 
Pyk2K457A. After 3 days, cells were counted and added to migration chambers. The 
following day, the distance migrated at 0 and 6 hr was calculated. A) Representative images 
are shown. Dashed lines indicates leading cell edge. Solid bar indicates scale bar at 100 μm. 
B) The distance migrated as a percentage of WT osteoblasts is shown. The data shown are 
average % migration ± SEM of 4 experiments. The asterisks indicate statistical significance 
compared to WT (p<0.05). C) Western blotting was used to confirm virus-expressed Pyk2 
relative to WT controls. A non-specific protein band seen by the Pyk2 antibody is indicated. 
Experiments were replicated more than 5 times. A representative blot is shown which 
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demonstrates higher Pyk2Y402F and lower Pyk2K457A levels compared to Pyk2-KO + 
Pyk2WT virus or WT osteoblasts.
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Fig. 4. Differential regulation of Pyk2 phosphorylation in osteoblasts by MKs and PMA
(A) Osteoblasts were cultured with MKs for 1, 16 or 24 hours. MKs were removed by 
extensive washing and osteoblasts were treated with 200 nM PMA or vehicle for 1 hour. 
Western blotting was performed for total Pyk2 or phosphorylated Pyk2-Y402 (pY402) as 
indicated. Densitometry was performed using ImageJ software and used to calculate the 
ratio of pY402/Pyk2. Studies were replicated 3 times and representative data are shown. (B) 
Osteoblasts were co-cultured with MKs for 10 days and assayed for ALP activity. The 
average ± standard deviation from 4 separate osteoblast experiments and 8 separate 
osteoblast + MKs experiments are shown. In each experiment triplicate cultures were 
assayed. The asterisk (*) indicates statistical significance for ALP activity in OB+MK 
compared to the OB control.
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Fig. 5. MKs promote osteoblast migration in the absence of Pyk2
Calvarial osteoblasts from WT mice or Pyk2-KO mice were plated at a similar density in 
migration chambers. The next morning, MKs were added to chamber slides (0 hour) and 
osteoblasts were imaged. After 6 hours, the wells were re-imaged and the distance traveled 
in the presence or absence of MKs was calculated and expressed as a percentage of the 0 
hour control. (A; C) Representative cell images at 0 and 6 hours for WT and Pyk2-KO 
osteoblasts, respectively. The dashed line indicates the leading edge of osteoblasts and solid 
white bar indicates scale bar (100 μm). (B; D) Data represent the average of 3 independent 
studies expressed as a percentage of the genotype-matched control. Although the basal 
migration of Pyk2-KO is elevated compared to WT osteoblasts (see Fig. 3). MKs 
significantly increase the migration of both (B) WT osteoblasts and (D) Pyk2-KO 
osteoblasts to a similar extent. Asterisks (*) indicate statistical significance for the effects of 
MKs on WT or Pyk2-KO osteoblasts compared no MKs (p<0.05).
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